Delving into the Latest Updates on CHO Pharma, Inc. with Synapse

Overview

Basic Info

Introduction

Established in March 2013, CHO Pharma, Inc. is a biopharmaceutical company that concentrates on leveraging advanced sugar platform technology to develop new drugs and address the treatment and diagnosis of carbohydrate-related diseases. The company's mission is to lead advancements in the area of sugar molecular technology by creating highly effective pharmaceuticals that possess few side effects. Furthermore, CHO Pharma, Inc. aims to improve patient care by developing precise early detection methods through its innovative research and development efforts and specialized expertise.

Tags

Neoplasms

Infectious Diseases

Immune System Diseases

Small molecule drug

Protein drugs

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Infectious Diseases	2
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	2
Protein drugs	1
Monoclonal antibody	1

Top 5 Target	Count

CD20(B-lymphocyte antigen CD20)	1

This is a 2-part study. Part 1/Phase 1 of the study will be conducted to determine the safety and tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma. It will also determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D).
Part 2/Phase 2a will assess the anticancer activity and safety of CHO-H01 plus lenalidomide in subjects with low-grade relapsed/refractory CD20+ non-Hodgkin's lymphoma.

Start Date15 Jan 2020

Sponsor / Collaborator

CHO Pharma, Inc.

NCT03221348 / Unknown statusPhase 1

A Phase I Open-label, Multiple Dose Study of CHO-H01 Administered Intravenously as a Single Agent to Subjects With Refractory or Relapsed Follicular Lymphoma

This is a single-arm open label trial to explore the tolerability, safety, PK, PD, and anti-tumor activity of various doses and schedules of CHO-H01 administered as monotherapy in subjects with follicular lymphoma.
Groups of 6 subjects are planned for each cohort. The first 3 patients of each cohort will be evaluated to determine if it is appropriate to proceed with the additional 3 patients at that dose and schedule.

Start Date01 Mar 2018

Sponsor / Collaborator

CHO Pharma, Inc.

100 Clinical Results associated with CHO Pharma, Inc.

Login to view more data

0 Patents (Medical) associated with CHO Pharma, Inc.

Login to view more data

7

Literatures (Medical) associated with CHO Pharma, Inc.

01 Jul 2021·Bioorganic ChemistryQ2 · CHEMISTRY

Development of biotinylated and magnetic bead-immobilized enzymes for efficient glyco-engineering and isolation of antibodies

Q2 · CHEMISTRY

Article

Author: Hung, Ting-Chun ; Tsai, Charng-Sheng ; Zeng, Yi-Fang ; Liao, Jung-Yu ; Chu, Kuo-Ching ; Chiu, Chih-Wei ; You, Tsai-Hong ; Shivatare, Sachin S ; Chuang, Hong-Yang ; Huang, Lin-Ya ; Huang, Chiu-Chen ; Wu, Chung-Yi ; Chao, Ping ; Lin, Nan-Horng

The chemoenzymatic remodeled monoclonal antidodies with well-defined glycan structure at the Fc domain display improved biological activities, such as ADCC and ADCP, and are more likely to yield a better safety profile by eliminating the non-human glycans derived from CHO cell culture. We covalently immobilize wild type endoglycosidase S (EndoS), fucosidase, and EndoS2 mutant on magnetic beads through a linker to efficiently generate homogeneous antibody glycoforms without additional purification step to remove endoglycosidase and fucosidase. We also used the biotinylated wild type EndoS2 and EndoS2 mutant in combination with covalently immobilized fucosidase on magnetic beads to allow the sequential removal of endoglycosidases and fucosidase for efficient glyco-engineering and isolation of antibodies without purifying deglycosylated antibody intermediate. Notably, the relatively expensive fucosidase can be recovered to reduce the cost, and the strong affinity of streptavidin to biotin would complete the isolation of biotinylated enzymes. We used Trastuzumab as a model to demonstrate both approaches were reliable for the large-scale production and isolation of antibodies without the residual contamination of endoglycosidase to avoid deglycosylation over storage time.

01 Nov 2020·Journal of Chromatography AQ2 · CHEMISTRY

Enhancement of fucosylated N-glycan isomer separation with an ultrahigh column temperature in porous graphitic carbon liquid chromatography-mass spectrometry

Q2 · CHEMISTRY

Article

Author: Ren, Chien-Tai ; Wu, Chung-Yi ; Lin, Ya-Ping ; Chen, Chung-Hsuan ; Shivatare, Sachin S ; Lin, Nan-Hon ; Lin, Jung-Lee ; Chen, Chein-Hung

Due to the heterogeneous and isomeric nature of glycans, the development of an advanced separation of distinct glycan isomers is essential for glycan research and application. In this study, we utilized porous graphite carbon (PGC) chromatography for the separation of isomeric oligosaccharides without reduction or chemical derivatization at 190 °C in a custom-built heating oven. Furthermore, the fine structures of glycan isomers could be identified by using ultrahigh temperature PGC liquid chromatography mass spectrometry (UHT-PGC-LCMS). A nonreduced hydrolyzed dextran was applied to verify the performance of UHT-PGC. When the temperature of the PGC column was increased from 25 to 190 °C, the liquid chromatography separation power of the nonreduced dextran ladder significantly increased. The advantage of the UHT-PGC column was its high peak capacity with gradient elution in 10 min at 190 °C, 6700 psi, and a 250 μL/min flow rate for native glycan analysis. Four synthetic Lewis antigen isomers were used to elucidate the separation effectiveness in UHT-PGC. Moreover, mass spectrometry-based sequencing to generate specific diagnostic ions from the four synthetic Lewis antigens was used to predict isomeric glycans based on the relative intensity ratio (RIR) of diagnostic ions. The intensities of the diagnostic ions of synthetic isomers were used to identify each isomer of the fucosylated glycan. The results clearly showed that terminal Lewis A and X residues were in the 3- and 6-arms of N-glycan, respectively.

01 Apr 2016·Nature ChemistryQ1 · CHEMISTRY

Modular synthesis of N-glycans and arrays for the hetero-ligand binding analysis of HIV antibodies

Q1 · CHEMISTRY

Article

Author: Lin, Yih-Shyan ; Kwong, Peter D ; Tseng, Susan Yu ; Shih, Hao-Wei ; Burton, Dennis R ; Tsai, Tsung-I ; Wu, Chung-Yi ; Pawar, Sujeet ; Lee, Chang-Chun David ; Chang, Shih-Huang ; Wong, Chi-Huey ; Liang, Chi-Hui ; Cheng, Yang-Yu ; Shivatare, Vidya S ; Zeng, Yi-Fang ; Ren, Chien-Tai ; Shivatare, Sachin S ; Tsai, Charng-Sheng

A new class of broadly neutralizing antibodies (bNAbs) from HIV donors has been reported to target the glycans on gp120--a glycoprotein found on the surface of the virus envelope--thus renewing hope of developing carbohydrate-based HIV vaccines. However, the version of gp120 used in previous studies was not from human T cells and so the glycosylation pattern could be somewhat different to that found in the native system. Moreover, some antibodies recognized two different glycans simultaneously and this cannot be detected with the commonly used glycan microarrays on glass slides. Here, we have developed a glycan microarray on an aluminium-oxide-coated glass slide containing a diverse set of glycans, including homo- and mixed N-glycans (high-mannose, hybrid and complex types) that were prepared by modular chemo-enzymatic methods to detect the presence of hetero-glycan binding behaviours. This new approach allows rapid screening and identification of optimal glycans recognized by neutralizing antibodies, and could speed up the development of HIV-1 vaccines targeting cell surface glycans.

100 Deals associated with CHO Pharma, Inc.

Login to view more data

100 Translational Medicine associated with CHO Pharma, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

2

Preclinical

Phase 2 Clinical

1

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CHO-H01 ( CD20 )	Non-Hodgkin Lymphoma More	Phase 2 Clinical
CHO-V08	Klebsiella Infections More	Preclinical
CHO-V07	Neoplasms More	Preclinical
CHO-S05	Influenza, Human More	Discovery
CHO-A04 ( SSEA-4 )	Neoplasms More	Pending